Evidence map›Paper›PMID 34362938›Full record

ArticleScientific reports2021

Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines.

Krzysztof Koras, Ewa Kizling, Dilafruz Juraeva, Eike Staub, Ewa Szczurek

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Krzysztof KorasFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland.
Ewa KizlingFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland.
Dilafruz JuraevaOncology Bioinformatics, Translational Medicine, Merck Healthcare KGaA, Darmstadt, Germany.
Eike StaubOncology Bioinformatics, Translational Medicine, Merck Healthcare KGaA, Darmstadt, Germany.
Ewa SzczurekFaculty of Mathematics, Informatics and Mechanics, University of Warsaw, Warsaw, Poland. szczurek@mimuw.edu.pl.
University of Warsaw · PLMerck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computational models for drug sensitivity prediction have the potential to significantly improve personalized cancer medicine. Drug sensitivity assays, combined with profiling of cancer cell lines and drugs become increasingly available for training such models. Multiple methods were proposed for predicting drug sensitivity from cancer cell line features, some in a multi-task fashion. So far, no such model leveraged drug inhibition profiles. Importantly, multi-task models require a tailored approach to model interpretability. In this work, we develop DEERS, a neural network recommender system for kinase inhibitor sensitivity prediction. The model utilizes molecular features of the cancer cell lines and kinase inhibition profiles of the drugs. DEERS incorporates two autoencoders to project cell line and drug features into 10-dimensional hidden representations and a feed-forward neural network to combine them into response prediction. We propose a novel interpretability approach, which in addition to the set of modeled features considers also the genes and processes outside of this set. Our approach outperforms simpler matrix factorization models, achieving R [Formula: see text] 0.82 correlation between true and predicted response for the unseen cell lines. The interpretability analysis identifies 67 biological processes that drive the cell line sensitivity to particular compounds. Detailed case studies are shown for PHA-793887, XMD14-99 and Dabrafenib.

Indexed as

AlgorithmsDeep LearningBiomarkers, TumorComputer SimulationGene Expression Regulation, NeoplasticHumansNeoplasmsPrognosisProtein Kinase InhibitorsTumor Cells, CulturedBiomarkers, TumorProtein Kinase Inhibitors

Identifiers

PMID34362938
PMCPMC8346627
OpenAlexW3189729408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.